The impact of recurrent seizures and the associated comorbidities of epilepsy on the health and well-being of patients has long been an interest for providers who treat patients with epilepsy. Early on, treatments focused primarily on decreasing the frequency of seizures. Over time, the impact of comorbid illnesses such as depression and anxiety has become increasingly clear. However, it is easy for providers to lose sight of the fact that epilepsy is not just associated with a negative impact on quality of life, epilepsy is also associated with an increased mortality rate three times that of the general population (1). Treating epilepsy is not just about improving quality of life, it can have an impact on the actual quantity of life as well.
was seen in contrast to no increase in mortality for patients with new-onset epilepsy who were seizure free (1) . These data suggest that successful treatment of seizures may mitigate some or all of the increased mortality risk associated with epilepsy. It is unclear whether all forms of pharmacologic or surgical treatments would have the same beneficial effects.
The benefits of epilepsy surgery on mortality risk have been demonstrated in several previous series (2) (3) (4) (5) . The recent study by Sperling et al. represents over 8,000 person-years of data to further assess mortality risks after epilepsy surgery. This study is the largest cohort of epilepsy surgery patients, with 1,006 patients treated with epilepsy surgery and 104 patients treated without brain surgery (39 with vagal nerve stimulator and the remainder with only medical management). Neither group includes patients with known malignant brain tumors nor progressive neurologic diseases. A total of 89 deaths were observed, with 16 occurring in the nonsurgical group. A majority of the deaths (55) were of unknown cause. Sudden unexplained death in epilepsy (SUDEP) or probable SUDEP accounted for 15 deaths. Cancer, trauma, suicide, cardiovascular disease, and miscellaneous causes accounted for the other 19 deaths. These data highlight a significant limitation in efforts to reduce mortality in epilepsy; it is difficult to prevent that which we do not fully understand. In this series, the true leading cause of death remains uncertain. With the large number of unknowns, any one of the causes noted above, or something that was not noted, could theoretically be the most frequent cause of death if it comprises a majority or near-majority of these cases. OBJECTIVE: To assess whether epilepsy surgery is associated with a reduction in mortality rate and if postoperative seizure frequency and severity affect mortality. METHODS: A total of 1,110 patients were evaluated (1,006 surgically and 104 nonsurgically treated) for a total follow-up of 8,126.62 person-years from 1986 to 2013. Deaths were ascertained through database and Social Security Death Index query. Patients were grouped by surgery type and seizure status; standardized mortality ratio and deaths per 1,000 person-years were calculated. Survival analysis and Cox proportional hazard regression were performed. RESULTS: Eighty-nine deaths were observed. Surgically treated patients had a lower mortality rate (8.6 per 1,000 person-years [95% confidence interval (CI) 6.58-11.15]) than nonsurgically treated patients (25.3 per 1,000 person-years [14.50-41.17]; p < 0.001). Seizure-free patients had a lower mortality rate (5.2 per 1,000 person-years [95% CI 2.67-9.02]) than non-seizure-free patients (10.4 per 1,000 person-years [95% CI 7.67-13.89] p = 0.03). More frequent postoperative tonic-clonic seizures (>2 per year) were associated with increased mortality (p = 0.006) whereas complex partial seizure frequency was not related to death rate. Mortality was similar in temporal and extratemporal epilepsy patients (p = 0.7). CONCLUSIONS: Brain surgery is associated with a reduction in mortality rate in drug-resistant epilepsy, both when seizures are abolished and when it results in significant palliation of tonic-clonic seizure frequency. These observations provide further rationale for earlier consideration of epilepsy surgery.
Living With Epilepsy: It's Not Just a Matter of Quality
The limitations on ascertainment of cause of death notwithstanding, these results further our understanding of the impact of epilepsy surgery on mortality. The surgically treated group had a lower mortality rate than the nonsurgically treated group (8.6 vs 25.3 deaths per 1,000 person-years, respectively). Patients who achieved seizure freedom following epilepsy surgery had a lower mortality rate versus those with continued seizures (5.2 vs 10.4 deaths per 1,000 person-years, respectively).
Although it is not the only source of mortality for persons with epilepsy, much of our attention has focused on SUDEP and strategies to decrease SUDEP risk. Seizure control has been one aspect of that focus, with specific attention paid to the increased risk of SUDEP for patients with tonic-clonic convulsions (6, 7) . The large size of this cohort allowed the authors to look at seizure frequency following surgery for both convulsions and focal (partial) seizures. Of the 909 patients who underwent focal epilepsy surgery (i.e., excluding patients that had a corpus callosotomy), 300 had postoperative-seizure frequency data with at least one convulsion. Patients with two or more convulsions had a death rate of 15.3 per 1,000 person-years, whereas the mortality rate for patients with 1 to 2 convulsions per year or <1 convulsion per year did not differ from that of seizure-free patients (3.3 or 3.8 deaths per 1,000 person-years, respectively).
There were 185 patients that had only focal (partial) seizures following a focal resection; for these patients, a lower mortality rate was seen than that of the nonsurgical group (10.2 vs 25.3 deaths per 1,000 person-years). Notably, within the nonsurgical group, nearly 62% of patients had convulsions, so some of this observed benefit may be secondary to palliation of tonic-clonic convulsions in the focal resection group.
The authors point out several potential limitations of their study, including the lack of data on comorbid illnesses, which certainly could have an impact on mortality. They also note the possibility of incomplete data from the Social Security Death Index, which may have led to an underestimation of the total number of deaths. Nonetheless, the authors have succeeded in clarifying several things to all providers who care for persons with epilepsy. First, we are reminded that treatment-resistant epilepsy is a life-threatening disease. In a survey of neurologists, over 60% reported discussing SUDEP rarely or not at all with patients (8) . In audits of local practice habits done in 2009 and again in 2012, an increased frequency of documentation of SUDEP discussions with patients was noted, with a rise from 4 to 34 percent of visits (9, 10) . SUDEP is not the only source of mortality for persons with epilepsy, but one could argue that it serves as a reasonable indicator of how much attention is paid to mortality issues in clinical encounters. Second, improving seizure control through epilepsy surgery has significant and measurable impacts on survival. Palliation of tonic-clonic convulsions, even with continued focal seizures, is a meaningful outcome in and of itself. Third, continued efforts to better ascertain the cause of death for persons with epilepsy may ultimately facilitate even better methods to decrease mortality. And finally, these data serve to bolster our call to action to providers treating persons with epilepsy. Medicine, ranging from public health initiatives to individual providers, has been increasingly aggressive about early treatment to mitigate long-term consequences and decrease mortality for a myriad of conditions. It is clear that treatment-resistant epilepsy should be added to this list of conditions that providers across the healthcare spectrum treat aggressively (in partnership with a comprehensive epilepsy center) in order to improve overall health and well-being.
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